The FDA has approved the investigational new drug application filed by Cerveau Technologies for its MK-6240, a tau PET imaging agent licensed from Merck. Cerveau will work with pharmaceutical partners to assess the tracer in imaging neurofibrillary tangles in the brain.
Cerveau's IND for tau PET tracer wins FDA approval
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.